Skip to main content
Acrivon Therapeutics, Inc. logo

Acrivon Therapeutics, Inc. — Investor Relations & Filings

Ticker · ACRV ISIN · US0048901096 US Manufacturing
Open in API
Filings indexed 293 across all filing types
Latest filing 2026-05-22 Proxy Solicitation & In…
Country US United States of America
Listing US ACRV

About Acrivon Therapeutics, Inc.

https://acrivon.com/

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology. The company's core technology is its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, which uses proteomics to identify the biologic drivers of cancer in individual patients. This platform enables the development of OncoSignature companion diagnostic tests designed to match patients with therapies predicted to be most effective for their specific tumor biology, a method distinct from genomic-based approaches. Acrivon's pipeline focuses on DNA Damage Response and cell cycle regulators. Its lead drug candidate, ACR-368 (prexasertib), is a selective kinase inhibitor in Phase 2 clinical trials for multiple solid tumor types. The pipeline also includes ACR-2316, a dual WEE1/PKMYT1 inhibitor. The company leverages its AP3 platform for internal drug development and for strategic co-development partnerships.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement
2026-05-22 English
ARS - Acrivon Therapeutics, Inc. (0001781174) (Filer)
Annual Report
2026-04-30 English
DEF 14A - Acrivon Therapeutics, Inc. (0001781174) (Filer)
Proxy Solicitation & Information Statement
2026-04-30 English
S-8 - Acrivon Therapeutics, Inc. (0001781174) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as equity incentive plans and employee stock purchase plans. It includes details about the number of shares registered, references prior S-8 filings, and incorporates by reference other filings like the Annual Report on Form 10-K. The document is not a financial report, earnings release, or management discussion, but a registration statement for securities issuance under employee plans. This type of filing corresponds to a capital/financing update related to share registration for employee compensation plans.
2026-03-19 English
8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. It includes a press release announcing financial results for the fourth quarter and full year ended December 31, 2025, and a corporate presentation update. The document explicitly states that the press release and presentation are furnished as exhibits and incorporated by reference, and the information is not deemed "filed" for certain regulatory purposes. The document itself is a regulatory filing announcing these events rather than the full financial report or presentation. The length is 4760 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this is best classified as a Regulatory Filing (RNS) rather than an Earnings Release (ER) or Investor Presentation (IP) because it is a Form 8-K current report announcing these materials rather than the materials themselves.
2026-03-19 English
10-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)
Annual Report FY 2025
2026-03-19 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.